Treatment (saracatinib) for Prostate Cancer

Phase 2

Waitlist Available

Led By Primo Lara

Research Sponsored by National Cancer Institute (NCI)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from start of treatment, up to 5 years

Awards & highlights

No Placebo-Only Group

Summary

This phase II trial is studying how well AZD0530 works in treating patients with prostate cancer that did not respond to hormone therapy. AZD0530 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth

Eligible Conditions

Prostate Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from start of treatment, up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from start of treatment, up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and from start of treatment, up to 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

PSA Response Rate

Secondary study objectives

Overall Survival

Progression-free Survival (PFS)

Time to Treatment Failure

+1 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (saracatinib)Experimental Treatment2 Interventions

Patients receive oral AZD0530 once daily. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Saracatinib

Not yet FDA approved

Do I qualify?Apply below to find out